Safety, improved outcomes with cystic fibrosis triple therapy maintained through 96 weeks

safety improved outcomes with cystic fibrosis triple therapy maintained through 96 weeks

Sumary of Safety, improved outcomes with cystic fibrosis triple therapy maintained through 96 weeks:

  • Poster 681. Presented at: North American Cystic Fibrosis Conference;
  • Back to Healio Safety and improvements in lung function, respiratory symptoms and CFTR function with elexacaftor/tezacaftor/ivacaftor were maintained through 96 weeks of treatment in patients with cystic fibrosis and at least one F508del allele.
  • Daines, MD, professor, division chief and director at the Cystic Fibrosis Center at University of Arizona and Banner Health, presented 96-week interim results from an ongoing open-label extension study of elexacaftor/tezacaftor/ivacaftor (Trikafta, Vertex Pharmaceuticals).
  • Improvements with triple therapy in pivotal phase 3 trials previously reported were maintained in the open-label extension.
  • The open-label extension study included 506 participants with cystic fibrosis aged 12 years and older (mean age, 26.7 years;
  • 49.6% female) with F508del and a minimal function mutation (n = 399) or who were homozygous for F508del (n = 107) from the phase 3 pivotal parent studies.
  • All participants received at least one dose of elexacaftor/tezacaftor/ivacaftor and enrolled in the open-label extension study.
  • 67 per year) were lower in the extension study compared with the placebo group in the parent study that included participants who were heterozygous for F508del and a minimal function mutation.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close